Senti Biosciences (SNTI) Liabilities from Discontinued Operations (2022 - 2023)
Senti Biosciences' quarterly Liabilities from Discontinued Operations came in at 243000.0 in Q4 2023, down 79.49% year-on-year from 1185000.0 in Q4 2022, and up 12.5% quarter-over-quarter from 216000.0 in Q3 2023.
Senti Biosciences has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 243000.0 in Q4 2023.
- For the quarter ending Q4 2023, Liabilities from Discontinued Operations fell 79.49% year-over-year to 243000.0; the trailing twelve-month figure through Dec 2023 stood at 243000.0 (down 79.49% YoY), and the FY2023 full-year result was 243000.0, down 79.49% from the prior year.
- Liabilities from Discontinued Operations for Q4 2023 stood at 243000.0, up from 216000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 1185000.0 in Q4 2022, with the low at 216000.0 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 243,000.00 |
| Dec 31, 2023 | 243,000.00 |
| Sep 30, 2023 | 216,000.00 |
| Sep 30, 2023 | 216,000.00 |
| Dec 31, 2022 | 1.19 Mn |
| Dec 31, 2022 | 1.19 Mn |